title: Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction.
abstract: BACKGROUND
  Multiple studies have demonstrated a relationship between creatine kinase-MB (CK-MB) elevation after percutaneous coronary intervention (PCI) and increased late mortality within the general population. Because CK-MB is frequently elevated in renal disease even in the absence of myocardial injury, the clinical significance of CK-MB elevation after PCI in patients with renal insufficiency has been questioned.
  
  
  METHODS
  We sought to examine the association between elevated CK-MB after PCI and late mortality in 190 consecutive patients with chronic renal insufficiency (serum creatinine > or =2.0 mg/dL) undergoing PCI at the Cleveland Clinic between January 1997 and March 2000. Of the total group, 20 patients undergoing PCI for acute myocardial infarction, cardiogenic shock, or both were excluded. Follow-up was 99.4% complete at a mean duration of 24.8 +/- 11.2 months (range 5-43 months).
  
  
  RESULTS
  CK-MB elevation above the upper limit of normal after intervention was detected in 33 patients (19.4%). Baseline characteristics were not significantly different between the CK-MB elevation group and the normal CK-MB group. Late mortality, however, was significantly higher among patients with postprocedural CK-MB elevation (36.4% vs 17.5%, P =.017). Cox proportional hazard model revealed CK-MB elevation as an independent predictor of late mortality (hazard ratio 2.44, 95% CI 1.14-5.24, P =.02), in addition to New York Heart Association class (hazard ratio 1.35, 95% CI 1.05-1.73, P =.02).
  
  
  CONCLUSIONS
  This analysis of patients with chronic renal insufficiency undergoing PCI suggests that postprocedural CK-MB elevation is an independent predictor of late mortality even in the presence of renal dysfunction.
authors.affiliation: Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: Allen
authors.initials: A
authors.lastname: Jeremias
authors.forename: Abdulhay
authors.initials: A
authors.lastname: Albirini
authors.forename: Khaled M
authors.initials: KM
authors.lastname: Ziada
authors.forename: Derek P
authors.initials: DP
authors.lastname: Chew
authors.forename: Sorin J
authors.initials: SJ
authors.lastname: Brener
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Ellis
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000150:complications / Q000401:mortality / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood*; D052283:Creatine Kinase, MM Form; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000401:mortality; D008297:Male; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D015607:Stents
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents; D007527:Isoenzymes; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D003402:Creatine Kinase; D052283:Creatine Kinase, MM Form